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Purpose/Objective: The purpose was to design and implement a 
comprehensive computerised calculation program to execute 
radiation-shielding evaluations for radiotherapy. The program 
addresses both individual and collective contributing factors that are 
intrinsic to shielding calculations e.g. building construction, treatment 
equipment and delivery techniques, workload and occupancy. It 
incorporates modern and emerging novel treatment delivery 
techniques and the resulting overall effects on radiation protection 
required. The secondary aim was to verify the shielding program by 
applying it to existing bunkers where measurements of photon and 
neutron doserate were made and to identify its advantages for 
modelling future radiotherapy bunkers. 
Materials and Methods: The calculation methods used to establish the 
photon and associated neutron dose rates employ the theoretical 
approach from the NCRP Report 151, and the IAEA Safety Report No. 
47, among others. The advantage of including new treatment 
techniques (extra-cranial stereotactic and ablative RT,VMAT, FFF, 
robotic radio-surgery) and newly available constructional materials 
improves the usefulness of the program for any radiotherapy centre. 
The program can evaluate existing bunkers for changes in workload, 
treatment technique or delivery. It contains all variables to enable 
modelling of a new build using concrete,high-density materials and 
layered materials. Calculations using actual workload compared to 
'worst -case' scenarios and the consequences on construction costs 
were evaluated. The contributions of photon, neutron scatter and 
neutron capture gamma rays were investigated with differing maze 
geometries. Special topics such as skyshine and ozone production 
were included too. The program includes all necessary TVLs and other 
intrinsic data, for modelling the spectrum of nominal photon energies 
clinically available, including flattened and flattening-filter-free (FFF) 
beam data. 
Results: The program’s logic and accuracy was successfully validated 
by comparison to literature and using measurements taken at two 
sites with different bunker designs. The program was used to 
calculate potential shielding changes to an existing bunker due to 
increasing the beam energy. The results showed adequate shielding 
except at the maze entrance. The impact of actual workloads versus 
theorised workload was also investigated. There was a 10-20% 
reduction in shielding when the workload theorised in 2003 was 
compared to actual 2012 workload for three bunkers, which could 
reduce the building costs by 10%. 
Conclusions: A comprehensive calculation program for bunker 
shielding was developed to include contemporary and emerging 
treatment methods. Its accuracy and functionality were proven in the 
case studies. It is more functional and manageable than previous 
programs used at the institution.  
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Purpose/Objective: To teach and train a large group of medical 
physicists, dosimetrists and radiation oncologists, working in different 
centres, in proton treatment planning. 
Materials and Methods: A common treatment planning system (TPS) 
for protons is since January 2012 installed and accessible for users in 
seven hospitals. We formed a school to provide the group with a 
common knowledgebase in proton treatment planning. The school 
started with a face-to-face meeting with lectures and workshops and 
continued with biweekly teleconferences. Prior to the teleconference 
the centres were expected to create treatment plans for selected 
patient cases in the common TPS. During the teleconferences, led by 
a chairman, the desktop of the common TPS was shared for everyone 
to view. The teleconferences consisted mainly of discussions about 
the suggested plans, patient fixation, VOI margins, dose distributions 
and plan robustness. We used a check-list to make sure we evaluated 
most relevant issues. After half a year, we changed focus and each 
centre in turn presented a case from their own database. A proton 
plan was created and compared with the actually given photon plan. 
Also here a checklist was used. To prepare for these sessions a number 
of scientific articles regarding related topics were distributed for 
discussions in the group. The TPS vendor also provided a proton 
planning course for this group. A second face-to-face meeting will 
deal with topics like creating common methods for different 
treatment sites, CT calibration, target delineation and study 
protocols. Yet another issue will be to plan future projects for the 
school, e.g. the possibility to invite external lecturers to the school. 
Results: The school has worked out well. All centres have participated 
actively both in planning and discussing, helping each other in gaining 
experience in a field where we are novices, and where the experience 
of this TPS varied within the group. It has been demanding to get the 
radiation oncologists involved. There may be several reasons for this; 
lack of staff, the school has not been properly entered into their work 
schedule or that they are merely used to evaluate plans, rather than 
to discuss the planning process itself, which has been an important 
part of the school. 
Conclusions: The concept is good for any topic were a common base 
line in knowledge is needed, but also as a mean to raise this level. It 
can be used for almost any topic, any number of participants and from 
any computer with a web camera to a conference room with a full 
scale teleconference system. Nevertheless the initial form may need 
revision over time to fit the purpose and the participants. A high 
standard of the teleconference systems is helpful when many people 
are participating. 
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Purpose/Objective: To investigate the association between various 
risk factors, including single nucleotide polymorphisms (SNPs) in 
candidate genes involved in radiation response, and late complications 
to radiotherapy in nasopharyngeal cancer patients. 
Materials and Methods: 155 patients were included in the study. 
Normal tissue fibrosis was scored using RTOG/EORTC grading system. 
11 candidate genes (ATM, XRCC1, XRCC3, XRCC4, XRCC5, PRKDC, 
LIG4, TP53, HDM2, CDKN1A, TGFB1) were selected for their presumed 
influence on radiosensitivity. 45 SNPs (12 primary and 33 neighboring) 
were genotyped by direct genomic DNA sequencing. 
Results: Patients with severe fibrosis (cases, G3-4, n = 48) were 
compared to controls (G0-2, n = 107). Univariate analysis showed 
significant association (P < 0.05) with radiation complications for 6 
SNPs (ATM G/A rs1801516, HDM2 promoter T/G rs2279744 and T/A 
rs1196333, XRCC1 G/A rs25487, XRCC5 T/C rs1051677 and TGFB1 C/T 
rs1800469). In addition, Kaplan-Meier analyses have also invoked 
significant association between genotypes and length of patients' 
follow up after radiotherapy. Multivariate logistic regression has 
further sustained these results suggesting predictive and prognostic 
roles of SNPs. 
Conclusions: Univariate and multivariate analysis suggest that 
radiation toxicity in radiotherapy patients are associated with certain 
SNPs, in genes involved in DNA repair pathways, including HDM2 gene 
promoter studied for the 1st time. In addition, radiosensitive patients 
harbored significantly higher number of risk alleles than controls (P < 
0.001). These results support the use of SNPs as genetic predictive 
markers for clinical radiosensitivity and the use of genotypes 
containing protective alleles as prognostic markers for patients' length 
of follow up after radiotherapy. Funded by KFSHRC grant 2000 031 and 
2040 025.  
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Purpose/Objective: The deaths due to radiation pneumonitis and 
fibrosis seen in the lethally-irradiated victims of the Tokai-mura 
incident form part of the characteristic spectrum of outcomes seen in 
late responding tissues that make up the radiation-induced multi-
organ dysfunction syndrome (RI-MODS). Additionally, we have 
identified an increased sensitivity in previously irradiated animals to 
otherwise survivable insults experienced in the months to years post-
injury, with a differential response between those animals irradiated 
as adults versus neonates; we believe that this precipitated 
susceptibility may be mechanistically similar to overt RI-MODS. These 
observations have led us to incorporate multiple organs/endpoints, 
delayed insult and age into a screening system for testing potential 
mitigation agents for use in both accidental and therapeutic 
scenarios. 
Materials and Methods: Our group has developed an integrated 
preclinical testing system that, although individually focused on 
separate organs of interest, nonetheless, is integrated through 
common radiation delivery systems, drug delivery protocols and 
assessment tools. Murine models investigating the delayed radiation 
response in lung, the central nervous system, erythropoietic bone 
marrow, skin and immune systems have been developed and verified. 
Mitigating agents are delivered no earlier than 3 days post-radiation 
and models are followed for up to 18 months prior to sacrifice. 
Results: A number of agents now have undergone preliminary testing 
using our model, including agents targeted at free radicals, 
inflammation, as well as specific signaling molecules. Early results 
indicate the utility of this system in identifying potential efficacy in 
individual organs or tissues, as well as, importantly, possible areas of 
clinical concern. Both the model and critical drug data will be 
presented. 
Conclusions: There is a significant need for the development of 
agents targeted at delayed radiation-induced effects in the context of 
whole body irradiation. We have introduced a preclinical testing 
system that provides a broad test-bed for screening potential 
mitigation candidates. Importantly, its focus on several critical organs 
allows for multiple endpoints to be assessed, thereby allowing for 
broad spectrum mitigation strategies to be developed, whilst allowing 
for the identification of possible areas of toxicity that may adversely 
affect and/or limit wide-scale treatment protocols. Furthermore, 
through this system, we have identified sensitivity to secondary, 
delayed insults (e.g. trauma, infection), particularly in special 
populations, such as children, suggesting that multiple treatment 
strategies may need to be developed dependent on age at time of 
irradiation.  
This work was supported by the Center for Medical Counter measures 
against Radiation Program, NIAID 1 U19-AI091036-03.  
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Purpose/Objective: Adjuvant treatment of breast cancer is commonly 
associated with the development of pulmonary injury and 
inflammation. The aim of the study was to investigate changes in 
serum levels of surfactant protein-D (SP-D), a potential specific 
marker of lung disease, during postoperative breast cancer therapy 
incorporating irradiation combined with administration of trastuzumab 
or hormone therapy. 
Materials and Methods: A total of 38 patients with primary breast 
cancer, aged between 30 and 76 years (median = 51.5 years), were 
monitored throughout a three-month period starting prior to the 
initiation of radiation therapy (RT) and until two months after the 
completion of RT. Serum levels of SP-D were serially determined at 
four predefined time-points in all patients and 31 healthy controls, 
using enzyme linked immunosorbent assay. All assays were performed 
in duplicates. 
Results: No disease progression was observed after clinical 
examination, radiological imaging and quantitative assessment of 
cancer markers CEA and CA 15-3. Pre-radiotherapy levels of SP-D were 
significantly higher in breast cancer patients compared to healthy 
controls (p=0.0240). Serum SP-D expression exhibited a gradual 
increase during adjuvant therapy (p=0.0032). More specifically, a 
significant increase in SP-D levels was observed in patients treated 
with a combination of radiotherapy and trastuzumab (p=0.0310). SP-D 
levels exhibited a significantly lower rate of change in patients under 
treatment with irradiation and hormone therapy (p=0.0428). 
Conclusions: SP-D is abundantly produced by pulmonary alveolar type 
II and Clara cells, thus its corresponding circulating levels can 
effectively reflect alterations in the alveolar compartments and 
epithelium. In the absence of clinical and imaging evidence of acute 
therapy-induced complications, our observations of the rate of change 
of serum SP-D expression indicate that the combined administration of 
RT and trastuzumab in breast cancer patients is likely to be associated 
with the development of subclinical pulmonary inflammation. On the 
contrary, treatment with radiation and hormone therapy appears to 
exert a protective effect against pulmonary toxicity.  
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Purpose/Objective: To provide a dose-volume response analysis of 
patient-reported urinary incontinence after external beam radiation 
therapy (EBRT) for prostate cancer. 
Materials and Methods: The study population consisted of 302 long-
term prostate-cancer survivors who had been treated with pelvic 
radiation therapy to a total dose of 70 Gy at 2 Gy per fraction at the 
Sahlgrenska University Hospital in Sweden during 1993 – 2006 and 332 
non-irradiated control men from the Swedish Population Registry 
matched for age and residency. We used reactivated treatment data 
and delineated the entire urinary bladder following its outer contour 
to be able to export and analyse bladder dose-volume histograms. 
Patient-reported outcomes (PROs) were taken from a study-specific, 
validated, postal questionnaire including information on 
demographics, disease, treatment, quality of life and physical health 
including urinary symptoms [1]. Urinary incontinence was defined as 
'urinary leakage, more than a few drops, weekly or more often during 
the last six months'(cf. LENT-SOMA Grade 1-2 toxicity for 
bladder/urethra). We used Logistic regression to investigate a possible 
causal relationship between dose and the studied outcome. Dose-
volume response modelling was performed using the Logistic function 
with mean absorbed and fractionation-corrected dose (EQD2,3using the 
Linear-quadratic model with an α/β=3).Model was fitted to data using 
the maximum likelihood method with parameter confidence intervals 
(CIs) calculated with profile likelihood estimation. Using a grid-search, 
the dose parameter where probability of outcome is 50% (D50)was 
considered in increments of 0.1 Gy; the curve steepness parameter 
where probability of outcome is 50% (γ50) was considered in 
increments of 0.01. 
[1] Alsadius D., Radiother Oncol., 2011 Dec; 101(3):495-501. 
Results: The median follow-up for survivors was 7 years (range, 1 to 
14 years). Among the survivors, 15% reported incontinence versus 7% 
of the controls (prevalence ratio: 2.1, 95% CI: 1.3-3.4). Both absorbed 
and fractionation-corrected mean dose were significant predictors for 
the outcome (P=0.008 and P=0.011,respectively). The mean dose 
model including the control background symptom rate of 7% resulted 
in D50-values of 94.1 Gy for absorbed dose and 99.4 Gy3 for 
fractionation-corrected dose (68% CI: 81.5-123.3 and 83.5-139.0, 
respectively). Corresponding γ50-values were 1.14 and 1.02 (68% CI: 
0.87-1.47 and 0.79-1.31, respectively). 
